CN102574845B - 1H-咪唑并[4,5-c]喹啉酮衍生物 - Google Patents
1H-咪唑并[4,5-c]喹啉酮衍生物 Download PDFInfo
- Publication number
- CN102574845B CN102574845B CN201080034616.0A CN201080034616A CN102574845B CN 102574845 B CN102574845 B CN 102574845B CN 201080034616 A CN201080034616 A CN 201080034616A CN 102574845 B CN102574845 B CN 102574845B
- Authority
- CN
- China
- Prior art keywords
- pyridyl
- methyl
- pyridin
- substituted
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c(c(I=N)c1)c(*)c(nc2*)c1c(N*)c2N Chemical compound *c(c(I=N)c1)c(*)c(nc2*)c1c(N*)c2N 0.000 description 3
- ILJSWVQHMBZLGF-UHFFFAOYSA-O CC(C(N(c1c(cc(cc2)-c3c[n](CCO)nc3)c2ncc1N1C)C1=O)=C[NH2+]C)=N Chemical compound CC(C(N(c1c(cc(cc2)-c3c[n](CCO)nc3)c2ncc1N1C)C1=O)=C[NH2+]C)=N ILJSWVQHMBZLGF-UHFFFAOYSA-O 0.000 description 1
- QFIJKSTWURUFRZ-UHFFFAOYSA-O CC(C(N(c1c(cc(cc2)-c3cc(NC)c(C)nc3)c2ncc1N1C)C1=O)=C[NH2+]C)=N Chemical compound CC(C(N(c1c(cc(cc2)-c3cc(NC)c(C)nc3)c2ncc1N1C)C1=O)=C[NH2+]C)=N QFIJKSTWURUFRZ-UHFFFAOYSA-O 0.000 description 1
- MTAZFDCMIMJXOT-UHFFFAOYSA-N CC(C)(C(OC)=O)c1cc(B2OC(C)(C)C(C)(C)O2)cnc1 Chemical compound CC(C)(C(OC)=O)c1cc(B2OC(C)(C)C(C)(C)O2)cnc1 MTAZFDCMIMJXOT-UHFFFAOYSA-N 0.000 description 1
- RPNSOYPNMZVMIP-UHFFFAOYSA-N CC(C)N(C)c1cc(-c(cc2)cc3c2ncc(N2C)c3N(c3c[n](C)nc3C)C2=O)ccn1 Chemical compound CC(C)N(C)c1cc(-c(cc2)cc3c2ncc(N2C)c3N(c3c[n](C)nc3C)C2=O)ccn1 RPNSOYPNMZVMIP-UHFFFAOYSA-N 0.000 description 1
- BQCSJRADEZYOTK-UHFFFAOYSA-N CC(C)Oc1cccnc1Cl Chemical compound CC(C)Oc1cccnc1Cl BQCSJRADEZYOTK-UHFFFAOYSA-N 0.000 description 1
- WBCBEAMZUUVBPP-UHFFFAOYSA-N CC1(C)OB(c(cn2)cc(N)c2F)OC1(C)C Chemical compound CC1(C)OB(c(cn2)cc(N)c2F)OC1(C)C WBCBEAMZUUVBPP-UHFFFAOYSA-N 0.000 description 1
- KOXOOQHQJSHMQR-UHFFFAOYSA-N CC1(C)OB(c2cc(OCCOC)cnc2)OC1(C)C Chemical compound CC1(C)OB(c2cc(OCCOC)cnc2)OC1(C)C KOXOOQHQJSHMQR-UHFFFAOYSA-N 0.000 description 1
- MGJUKATWICYVTO-UHFFFAOYSA-N CC1(C)OB(c2cnc(COC(C)=O)c(Cl)c2)OC1(C)C Chemical compound CC1(C)OB(c2cnc(COC(C)=O)c(Cl)c2)OC1(C)C MGJUKATWICYVTO-UHFFFAOYSA-N 0.000 description 1
- CVBMAGJYSCBHHZ-UHFFFAOYSA-N CCN(C(OC(C)(C)C)=O)c1c(C)ncc(Br)c1 Chemical compound CCN(C(OC(C)(C)C)=O)c1c(C)ncc(Br)c1 CVBMAGJYSCBHHZ-UHFFFAOYSA-N 0.000 description 1
- VXLHQXRJOBYLKE-UHFFFAOYSA-N CCN(C(OC(C)(C)C)=O)c1cc(B2OC(C)(C)C(C)(C)O2)cnc1COC(C)=O Chemical compound CCN(C(OC(C)(C)C)=O)c1cc(B2OC(C)(C)C(C)(C)O2)cnc1COC(C)=O VXLHQXRJOBYLKE-UHFFFAOYSA-N 0.000 description 1
- SMTUAZLWXNWYDS-UHFFFAOYSA-N CCN(C)c1cncc(-c(cc2)cc3c2ncc(N2C)c3N(c3c[n](C)nc3C)C2=O)c1 Chemical compound CCN(C)c1cncc(-c(cc2)cc3c2ncc(N2C)c3N(c3c[n](C)nc3C)C2=O)c1 SMTUAZLWXNWYDS-UHFFFAOYSA-N 0.000 description 1
- DXUIXVDVXGBWQB-UHFFFAOYSA-N CCN(c1c(CO2)ncc(-c(cc3)cc4c3ncc(N3C)c4N(c4c[n](C)nc4C)C3=O)c1)C2=O Chemical compound CCN(c1c(CO2)ncc(-c(cc3)cc4c3ncc(N3C)c4N(c4c[n](C)nc4C)C3=O)c1)C2=O DXUIXVDVXGBWQB-UHFFFAOYSA-N 0.000 description 1
- HCMLRLSIBOHJAP-UHFFFAOYSA-O CCN(c1cc(-c(ccc2ncc3N4C)cc2c3N(C(C(C)=N)=C[NH2+]C)C4=O)cnc1N1C)C1=O Chemical compound CCN(c1cc(-c(ccc2ncc3N4C)cc2c3N(C(C(C)=N)=C[NH2+]C)C4=O)cnc1N1C)C1=O HCMLRLSIBOHJAP-UHFFFAOYSA-O 0.000 description 1
- AXUARBNISUDUFA-UHFFFAOYSA-N CCN(c1cnc(ccc(-c2cncc(N)c2)c2)c2c1N1c2c[n](C)nc2C)C1=O Chemical compound CCN(c1cnc(ccc(-c2cncc(N)c2)c2)c2c1N1c2c[n](C)nc2C)C1=O AXUARBNISUDUFA-UHFFFAOYSA-N 0.000 description 1
- ULRXENZPBYCHTI-UHFFFAOYSA-N CCNc(nc1)c(C(F)(F)F)cc1-c(cc1)cc2c1ncc(N1C)c2N(c2c(C)[n](C)nc2C)C1=O Chemical compound CCNc(nc1)c(C(F)(F)F)cc1-c(cc1)cc2c1ncc(N1C)c2N(c2c(C)[n](C)nc2C)C1=O ULRXENZPBYCHTI-UHFFFAOYSA-N 0.000 description 1
- LYWVUAHREBMRBE-UHFFFAOYSA-N CCNc1cc(-c(cc23)ccc2ncc(N2C)c3N(c3c[n](C)nc3Cl)C2=O)cnc1OC Chemical compound CCNc1cc(-c(cc23)ccc2ncc(N2C)c3N(c3c[n](C)nc3Cl)C2=O)cnc1OC LYWVUAHREBMRBE-UHFFFAOYSA-N 0.000 description 1
- OPRVJSBTLXNPNX-UHFFFAOYSA-N CCNc1cc(B2OC(C)(C)C(C)(C)O2)cnc1F Chemical compound CCNc1cc(B2OC(C)(C)C(C)(C)O2)cnc1F OPRVJSBTLXNPNX-UHFFFAOYSA-N 0.000 description 1
- MVSULRFHQNDJBA-UHFFFAOYSA-N CCNc1ncc(B2OC(C)(C)C(C)(C)O2)cc1COCC Chemical compound CCNc1ncc(B2OC(C)(C)C(C)(C)O2)cc1COCC MVSULRFHQNDJBA-UHFFFAOYSA-N 0.000 description 1
- MJJHCPMTZLNVJL-UHFFFAOYSA-N CCOC(c(cnc(cc1)c2nc1-c(cc1OC)ccc1OC)c2O)=O Chemical compound CCOC(c(cnc(cc1)c2nc1-c(cc1OC)ccc1OC)c2O)=O MJJHCPMTZLNVJL-UHFFFAOYSA-N 0.000 description 1
- KONZNGOVTYWGLU-UHFFFAOYSA-N CCOCc1c(N)ncc(B2OC(C)(C)C(C)(C)O2)c1 Chemical compound CCOCc1c(N)ncc(B2OC(C)(C)C(C)(C)O2)c1 KONZNGOVTYWGLU-UHFFFAOYSA-N 0.000 description 1
- RDJYEIGCVPHAAE-UHFFFAOYSA-N CCOc(ncc(B1OC(C)(C)C(C)(C)O1)c1)c1N(C)C(C)=O Chemical compound CCOc(ncc(B1OC(C)(C)C(C)(C)O1)c1)c1N(C)C(C)=O RDJYEIGCVPHAAE-UHFFFAOYSA-N 0.000 description 1
- VUMDMYLDLYPQTB-UHFFFAOYSA-O CC[NH2+]C=C(C(C)=N)N(c(c1cc(-c2cc(NC)cnc2)ccc1nc1)c1N1C)C1=O Chemical compound CC[NH2+]C=C(C(C)=N)N(c(c1cc(-c2cc(NC)cnc2)ccc1nc1)c1N1C)C1=O VUMDMYLDLYPQTB-UHFFFAOYSA-O 0.000 description 1
- VXMYXIOZMYNGFV-UHFFFAOYSA-N CC[n]1nc(C)c(N(c(c(cc(cc2)-c(cc3)cc(OCC)c3OCC)c2nc2)c2N2C)C2=O)c1 Chemical compound CC[n]1nc(C)c(N(c(c(cc(cc2)-c(cc3)cc(OCC)c3OCC)c2nc2)c2N2C)C2=O)c1 VXMYXIOZMYNGFV-UHFFFAOYSA-N 0.000 description 1
- ACMNIGFBKQQESM-UHFFFAOYSA-N CCc(c(N)c1)ncc1-c(ccc1ncc2N3C)cc1c2N(c1c[n](C)nc1C)C3=O Chemical compound CCc(c(N)c1)ncc1-c(ccc1ncc2N3C)cc1c2N(c1c[n](C)nc1C)C3=O ACMNIGFBKQQESM-UHFFFAOYSA-N 0.000 description 1
- PAZJHPLHBXUGOH-UHFFFAOYSA-N CN(c(cnc(c1c2)ccc2-c2ccc(NCCO)nc2)c1N1c2ccn[n]2C)C1=O Chemical compound CN(c(cnc(c1c2)ccc2-c2ccc(NCCO)nc2)c1N1c2ccn[n]2C)C1=O PAZJHPLHBXUGOH-UHFFFAOYSA-N 0.000 description 1
- BKWVCWSASGSHSS-UHFFFAOYSA-N CNc(ncc(Br)c1)c1N Chemical compound CNc(ncc(Br)c1)c1N BKWVCWSASGSHSS-UHFFFAOYSA-N 0.000 description 1
- PMFAMDOUBXZRSN-UHFFFAOYSA-N COc1c(CO)ncc(Br)c1 Chemical compound COc1c(CO)ncc(Br)c1 PMFAMDOUBXZRSN-UHFFFAOYSA-N 0.000 description 1
- AODRZGHQZRKHMI-UHFFFAOYSA-N C[n](cc1N(c(c(cc(cc2)-c(cc3CO)cnc3OC)c2nc2)c2N2C)C2=O)nc1Cl Chemical compound C[n](cc1N(c(c(cc(cc2)-c(cc3CO)cnc3OC)c2nc2)c2N2C)C2=O)nc1Cl AODRZGHQZRKHMI-UHFFFAOYSA-N 0.000 description 1
- YQYVREKMMCJFEM-UHFFFAOYSA-N Cc(c(N(c(c(cc(cc1)-c(cc23)cnc2OC)c1nc1)c1N1C)C1=O)c1)n[n]1/[O]=C3/NC Chemical compound Cc(c(N(c(c(cc(cc1)-c(cc23)cnc2OC)c1nc1)c1N1C)C1=O)c1)n[n]1/[O]=C3/NC YQYVREKMMCJFEM-UHFFFAOYSA-N 0.000 description 1
- MLWSAGOOTBLKTL-UHFFFAOYSA-N Cc(ncc(Br)c1)c1N(C)/S=[O]/C Chemical compound Cc(ncc(Br)c1)c1N(C)/S=[O]/C MLWSAGOOTBLKTL-UHFFFAOYSA-N 0.000 description 1
- AGUUEKWHHHDESY-UHFFFAOYSA-N Cc(ncc(Br)c1)c1OC(CF)CF Chemical compound Cc(ncc(Br)c1)c1OC(CF)CF AGUUEKWHHHDESY-UHFFFAOYSA-N 0.000 description 1
- GSHPNOIWKBBFMI-UHFFFAOYSA-N Cc1c(NC)ncc(-c(ccc2ncc3N4C)cc2c3N(c2c[n](C)nc2Cl)C4=O)c1 Chemical compound Cc1c(NC)ncc(-c(ccc2ncc3N4C)cc2c3N(c2c[n](C)nc2Cl)C4=O)c1 GSHPNOIWKBBFMI-UHFFFAOYSA-N 0.000 description 1
- SMIPWYASWWBPSN-UHFFFAOYSA-N Cc1n[n](C)cc1N(c(c(cc(cc1)-c(cc2)cc(OC)c2OC)c1nc1)c1N1)C1=O Chemical compound Cc1n[n](C)cc1N(c(c(cc(cc1)-c(cc2)cc(OC)c2OC)c1nc1)c1N1)C1=O SMIPWYASWWBPSN-UHFFFAOYSA-N 0.000 description 1
- VRPDYWGRNLIOBW-UHFFFAOYSA-N Cc1n[n](C)cc1N(c(c(cc(cc1)-c(cn2)cc(COC)c2OC)c1nc1)c1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c(c(cc(cc1)-c(cn2)cc(COC)c2OC)c1nc1)c1N1C)C1=O VRPDYWGRNLIOBW-UHFFFAOYSA-N 0.000 description 1
- XHNOXJZUOTVGFJ-UHFFFAOYSA-N Cc1n[n](C)cc1N(c(c(cc(cc1)-c2cc(NC)c(COC)nc2)c1nc1)c1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c(c(cc(cc1)-c2cc(NC)c(COC)nc2)c1nc1)c1N1C)C1=O XHNOXJZUOTVGFJ-UHFFFAOYSA-N 0.000 description 1
- DNXBDIOCYSMLRY-UHFFFAOYSA-N Cc1n[n](C)cc1N(c(c(cc(cc1)-c2cc(OC)c(COC)nc2)c1nc1)c1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c(c(cc(cc1)-c2cc(OC)c(COC)nc2)c1nc1)c1N1C)C1=O DNXBDIOCYSMLRY-UHFFFAOYSA-N 0.000 description 1
- DENBVUSAUKUMAN-UHFFFAOYSA-N Cc1n[n](C)cc1N(c(c(cc(cc1)-c2ccc(C(N)=O)nc2)c1nc1)c1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c(c(cc(cc1)-c2ccc(C(N)=O)nc2)c1nc1)c1N1C)C1=O DENBVUSAUKUMAN-UHFFFAOYSA-N 0.000 description 1
- SFZKNCLTLOKJOI-UHFFFAOYSA-N Cc1n[n](C)cc1N(c(c(cc(cc1)-c2cnc(cc[n]3C)c3c2)c1nc1)c1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c(c(cc(cc1)-c2cnc(cc[n]3C)c3c2)c1nc1)c1N1C)C1=O SFZKNCLTLOKJOI-UHFFFAOYSA-N 0.000 description 1
- XRYARIJYFLNCRO-GOSISDBHSA-N Cc1n[n](C)cc1N(c(c1cc(-c(cc2)cnc2N(CC2)C[C@@H]2O)ccc1nc1)c1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c(c1cc(-c(cc2)cnc2N(CC2)C[C@@H]2O)ccc1nc1)c1N1C)C1=O XRYARIJYFLNCRO-GOSISDBHSA-N 0.000 description 1
- HVDORYFRVKUDLZ-UHFFFAOYSA-N Cc1n[n](C)cc1N(c1c(cc(cc2)-c(cc3N4C)cnc3N(C)C4=O)c2ncc1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c1c(cc(cc2)-c(cc3N4C)cnc3N(C)C4=O)c2ncc1N1C)C1=O HVDORYFRVKUDLZ-UHFFFAOYSA-N 0.000 description 1
- AURCYJANPOULGD-UHFFFAOYSA-N Cc1n[n](C)cc1N(c1c(cc(cc2)-c3cnc4[n](C)c(N(C)C)nc4c3)c2ncc1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(c1c(cc(cc2)-c3cnc4[n](C)c(N(C)C)nc4c3)c2ncc1N1C)C1=O AURCYJANPOULGD-UHFFFAOYSA-N 0.000 description 1
- HIWGFMSZNIXIHF-UHFFFAOYSA-N Cc1n[n](CC(O)=O)cc1N(c(c(cc(cc1)Br)c1nc1)c1N1)C1=O Chemical compound Cc1n[n](CC(O)=O)cc1N(c(c(cc(cc1)Br)c1nc1)c1N1)C1=O HIWGFMSZNIXIHF-UHFFFAOYSA-N 0.000 description 1
- IJEKMVWDWDJZGF-UHFFFAOYSA-N Cc1n[n](CC(O)=O)cc1N(c(c(cc(cc1)Br)c1nc1)c1N1C)C1=O Chemical compound Cc1n[n](CC(O)=O)cc1N(c(c(cc(cc1)Br)c1nc1)c1N1C)C1=O IJEKMVWDWDJZGF-UHFFFAOYSA-N 0.000 description 1
- LINWTABTUUDLFL-UHFFFAOYSA-N Cc1n[n](CC(OC)=O)cc1N Chemical compound Cc1n[n](CC(OC)=O)cc1N LINWTABTUUDLFL-UHFFFAOYSA-N 0.000 description 1
- XVWPYPFUFDSLBZ-UHFFFAOYSA-N Cc1n[o]c(C)c1N(c(c1cc(Br)ccc1nc1)c1N1C)C1=O Chemical compound Cc1n[o]c(C)c1N(c(c1cc(Br)ccc1nc1)c1N1C)C1=O XVWPYPFUFDSLBZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18414109P | 2009-06-04 | 2009-06-04 | |
| US61/184,141 | 2009-06-04 | ||
| PCT/EP2010/057719 WO2010139731A1 (en) | 2009-06-04 | 2010-06-02 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102574845A CN102574845A (zh) | 2012-07-11 |
| CN102574845B true CN102574845B (zh) | 2015-09-02 |
Family
ID=42697442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080034616.0A Expired - Fee Related CN102574845B (zh) | 2009-06-04 | 2010-06-02 | 1H-咪唑并[4,5-c]喹啉酮衍生物 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8476294B2 (https=) |
| EP (1) | EP2438064A1 (https=) |
| JP (1) | JP5596137B2 (https=) |
| KR (1) | KR101445458B1 (https=) |
| CN (1) | CN102574845B (https=) |
| AR (1) | AR076949A1 (https=) |
| AU (1) | AU2010255727B2 (https=) |
| BR (1) | BRPI1010621A2 (https=) |
| CA (1) | CA2763821A1 (https=) |
| CL (1) | CL2011003052A1 (https=) |
| CO (1) | CO6470887A2 (https=) |
| CR (1) | CR20110608A (https=) |
| CU (1) | CU24064B1 (https=) |
| DO (1) | DOP2011000373A (https=) |
| EA (1) | EA020715B1 (https=) |
| EC (1) | ECSP11011500A (https=) |
| GE (1) | GEP20156267B (https=) |
| IL (1) | IL216452A0 (https=) |
| MA (1) | MA33332B1 (https=) |
| MX (1) | MX2011012943A (https=) |
| NI (1) | NI201100209A (https=) |
| NZ (1) | NZ596487A (https=) |
| PE (1) | PE20120224A1 (https=) |
| SG (1) | SG176572A1 (https=) |
| TN (1) | TN2011000626A1 (https=) |
| TW (1) | TWI464168B (https=) |
| UA (1) | UA106074C2 (https=) |
| UY (1) | UY32682A (https=) |
| WO (1) | WO2010139731A1 (https=) |
| ZA (1) | ZA201108439B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| JP2014504286A (ja) * | 2010-12-06 | 2014-02-20 | ピラマル エンタープライジーズ リミテッド | 置換イミダゾキノリン誘導体 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| WO2013071698A1 (zh) | 2011-11-17 | 2013-05-23 | 山东轩竹医药科技有限公司 | 三环类PI3K和/或mTOR抑制剂 |
| WO2014141118A1 (en) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
| BR112015025686B1 (pt) | 2013-04-15 | 2020-10-27 | Fmc Corporation | composto, composições fungicidas e método para o controle das doenças dos vegetais |
| JP6576929B2 (ja) * | 2013-09-11 | 2019-09-18 | メルク パテント ゲーエムベーハー | ヘテロ環化合物 |
| US9745321B2 (en) | 2013-09-30 | 2017-08-29 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof |
| JP6606428B2 (ja) * | 2013-10-11 | 2019-11-13 | 国立大学法人 東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| CN104447740B (zh) | 2013-11-20 | 2017-02-22 | 北京富龙康泰生物技术有限公司 | 咪唑酮类衍生物、其药物组合物和用途 |
| NO2714752T3 (https=) | 2014-05-08 | 2018-04-21 | ||
| JP6195684B2 (ja) | 2014-06-03 | 2017-09-13 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 |
| PL3560924T3 (pl) * | 2015-04-02 | 2021-10-11 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| BR112019007594A2 (pt) | 2016-10-13 | 2019-07-02 | Loyola University Of Chicago | método para bloquear a transmissão do parasita da malária |
| CN110072521B (zh) | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
| MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN115151253B (zh) * | 2019-09-23 | 2025-04-15 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| ES2974742T3 (es) | 2020-09-21 | 2024-07-01 | Wei Zhong | Compuestos de 1-(3,3-difluoropiperidin-4-il)-imidazo[4,5-c]quinolin-2-ona sustituidos con capacidad de penetración en la barrera hematoencefálica |
| CN115136336A (zh) * | 2021-01-26 | 2022-09-30 | 京东方科技集团股份有限公司 | 量子点发光器件、显示装置和制作方法 |
| CN116768928A (zh) * | 2023-06-15 | 2023-09-19 | 上海毕臣生化科技有限公司 | 一种3-叔丁基-5-硼酸酯基吡啶的合成方法 |
| CN117384154A (zh) * | 2023-09-04 | 2024-01-12 | 广州医科大学 | 一种吡咯并喹啉酮化合物、合成方法及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097641A2 (en) * | 2002-05-21 | 2003-11-27 | Novartis Ag | 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
| WO2005054238A1 (en) * | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases |
| WO2006122806A2 (en) * | 2005-05-20 | 2006-11-23 | Novartis Ag | 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors |
| WO2008103636A1 (en) * | 2007-02-20 | 2008-08-28 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
| WO2009013305A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| WO2010038165A1 (en) * | 2008-09-30 | 2010-04-08 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004014969D1 (de) | 2003-11-21 | 2008-08-21 | Novartis Ag | 1h-imidazochinolinderivate als proteinkinaseinhibitoren |
| US20080213308A1 (en) | 2004-09-14 | 2008-09-04 | Nicholas Valiante | Imidazoquinoline Compounds |
| KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
| RS53335B (sr) | 2006-11-20 | 2014-10-31 | Novartis Ag | Kristalna monotozilatna so 2-metil-2-[4-(3-metil-2-okso-8-hinolin-3-il-2,3-dihidro-imidazo[4,5-c]hinolin-1-il)-fenil]-propionitrila |
| US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| BRPI0909082A2 (pt) | 2008-03-26 | 2019-02-26 | Novartis Ag | imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf |
| EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
-
2010
- 2010-06-02 NZ NZ596487A patent/NZ596487A/xx not_active IP Right Cessation
- 2010-06-02 PE PE2011002047A patent/PE20120224A1/es not_active Application Discontinuation
- 2010-06-02 SG SG2011085487A patent/SG176572A1/en unknown
- 2010-06-02 CA CA2763821A patent/CA2763821A1/en not_active Abandoned
- 2010-06-02 EA EA201101704A patent/EA020715B1/ru not_active IP Right Cessation
- 2010-06-02 GE GEAP201012484A patent/GEP20156267B/en unknown
- 2010-06-02 JP JP2012513613A patent/JP5596137B2/ja not_active Expired - Fee Related
- 2010-06-02 CN CN201080034616.0A patent/CN102574845B/zh not_active Expired - Fee Related
- 2010-06-02 AU AU2010255727A patent/AU2010255727B2/en not_active Ceased
- 2010-06-02 US US12/792,471 patent/US8476294B2/en not_active Expired - Fee Related
- 2010-06-02 KR KR1020127000098A patent/KR101445458B1/ko not_active Expired - Fee Related
- 2010-06-02 MA MA34404A patent/MA33332B1/fr unknown
- 2010-06-02 WO PCT/EP2010/057719 patent/WO2010139731A1/en not_active Ceased
- 2010-06-02 UA UAA201114398A patent/UA106074C2/uk unknown
- 2010-06-02 EP EP10721029A patent/EP2438064A1/en not_active Withdrawn
- 2010-06-02 BR BRPI1010621A patent/BRPI1010621A2/pt not_active IP Right Cessation
- 2010-06-02 MX MX2011012943A patent/MX2011012943A/es active IP Right Grant
- 2010-06-02 AR ARP100101942A patent/AR076949A1/es unknown
- 2010-06-03 UY UY0001032682A patent/UY32682A/es not_active Application Discontinuation
- 2010-06-03 TW TW099117977A patent/TWI464168B/zh not_active IP Right Cessation
-
2011
- 2011-11-17 ZA ZA2011/08439A patent/ZA201108439B/en unknown
- 2011-11-17 IL IL216452A patent/IL216452A0/en not_active IP Right Cessation
- 2011-11-21 CR CR20110608A patent/CR20110608A/es unknown
- 2011-11-30 NI NI201100209A patent/NI201100209A/es unknown
- 2011-11-30 CU CU2011000221A patent/CU24064B1/es not_active IP Right Cessation
- 2011-12-02 EC EC2011011500A patent/ECSP11011500A/es unknown
- 2011-12-02 CL CL2011003052A patent/CL2011003052A1/es unknown
- 2011-12-02 DO DO2011000373A patent/DOP2011000373A/es unknown
- 2011-12-05 TN TNP2011000626A patent/TN2011000626A1/en unknown
- 2011-12-12 CO CO11170918A patent/CO6470887A2/es active IP Right Grant
-
2013
- 2013-05-24 US US13/901,849 patent/US20140005163A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097641A2 (en) * | 2002-05-21 | 2003-11-27 | Novartis Ag | 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
| WO2005054238A1 (en) * | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases |
| WO2006122806A2 (en) * | 2005-05-20 | 2006-11-23 | Novartis Ag | 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors |
| WO2008103636A1 (en) * | 2007-02-20 | 2008-08-28 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
| WO2009013305A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| WO2010038165A1 (en) * | 2008-09-30 | 2010-04-08 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102574845B (zh) | 1H-咪唑并[4,5-c]喹啉酮衍生物 | |
| US20100311714A1 (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | |
| JP5436507B2 (ja) | アザインドール | |
| US8188113B2 (en) | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| CA2451678C (en) | Azaindoles | |
| AU2013249041A1 (en) | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an HIV infection | |
| CN111868037B (zh) | 作为crhr2拮抗剂的稠合环状脲衍生物 | |
| CN105051047A (zh) | 化学个体 | |
| JP2021503479A (ja) | 置換ヘテロアリール化合物及び使用方法 | |
| US20240109900A1 (en) | Azabicyclic shp2 inhibitors | |
| CN118434744A (zh) | 含氮大环类化合物及其制备方法和医药用途 | |
| JP6847954B2 (ja) | キナーゼ阻害剤としての三環式化合物および組成物 | |
| JP4871474B2 (ja) | アザインドール | |
| US20250114345A1 (en) | Compounds and compositions as cbp/p300 degraders and uses thereof | |
| CN103596953A (zh) | 吡啶并萘啶类P13K和mTOR双重抑制剂及其制备与应用 | |
| CA2981365C (en) | Imidazolonylquinolines and the use thereof as atm kinase inhibitors | |
| HK40037565A (en) | Fused cyclic urea derivatives as crhr2 antagonist | |
| CA2981365A1 (en) | Imidazolonylquinolines and the use thereof as atm kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 Termination date: 20170602 |